FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2520709749> ?p ?o ?g. }

• W2520709749 endingPage "S733" @default.
• W2520709749 startingPage "S732" @default.
• W2520709749 abstract "Erlotinib (TARCEVAr) is an oral, epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor that has anti-tumor activity and good tolerability in non-small cell lung cancer (NSCLC). In particular, higher response rates have been noted in Oriental patients than Western patients. The aim of this study (EAP; Expanded Access Program) is to evaluate the efficacy and tolerability of erlotinib monotherapy as a palliative treatment for advanced NSCLC patients in Korea. Patients with histologically or cytologically confirmed stage IIIB or IV NSCLC including recurrent, or metastatic disease, with performance status from 0 to 3, were eligible either if they had received any anti-cancer treatment except EGFR inhibitors or if they were unsuitable for che-motherapy due to poor performance status. Enrolled patietns were treated with oral erlotinib, at a dose of 150 mg daily until disease progression or development of intolerable toxicity. The median age of the 120 patients was 61 years, and 63.3% were male; 89.1% were performance status 0-1; 50.8% had received one prior palliative chemotherapy regimens and 33.3% were two or more prior palliative regimens. Overall tumor response rate, including complete and partial response, was 23.3% and an additional 18.3% of patients achieved stable disease. Superior tumor responses were observed in females (p=0.001), never-smokers (p=0.047), and histology of adenocarcinoma (p<0.001). The most common adverse event was skin rash (78%), which were generally mild, but grade 3/4 skin rash occurred in 13% of all enrolled patietns. There is one treatment related mortality with pneumonia. With a median follow-up of 14.5 months, the median time to progression (TTP) was 2.7 months (95%CI; 2.2-3.2) and the me-dian overall survival (OS) has not been reached yet. Female (p<0.001), adenocarcinoma (p=0.01), never-smoker (p<0.001), and appearance of skin rash (p<0.001) were good prognostic factor for overall survival. In multivariate analysis, female gender and presented skin rash were better prognostic factors for survival. Erlotinib monotherapy showed clinically significant anti-tumor activity and an acceptable tolerability profile as a palliative treatment in advanced NSCLC patients in Korea, especially in females, never-smokers, patients with adenocarcinoma histology, and in cases with skin rash." @default.
• W2520709749 created "2016-09-23" @default.
• W2520709749 creator A5013255537 @default.
• W2520709749 creator A5022061532 @default.
• W2520709749 creator A5028872300 @default.
• W2520709749 creator A5030107272 @default.
• W2520709749 creator A5034739279 @default.
• W2520709749 creator A5045276990 @default.
• W2520709749 creator A5045345910 @default.
• W2520709749 creator A5051301531 @default.
• W2520709749 creator A5067307453 @default.
• W2520709749 creator A5084649631 @default.
• W2520709749 date "2007-08-01" @default.
• W2520709749 modified "2023-09-27" @default.
• W2520709749 title "P3-126: Erlotinib monotherapy for stage IIIB/IV non–small cell lung cancer: A prospective study by the Korean Cancer Study Group(KCSG)" @default.
• W2520709749 doi "https://doi.org/10.1097/01.jto.0000284101.66568.bd" @default.
• W2520709749 hasPublicationYear "2007" @default.
• W2520709749 type Work @default.
• W2520709749 sameAs 2520709749 @default.
• W2520709749 citedByCount "0" @default.
• W2520709749 crossrefType "journal-article" @default.
• W2520709749 hasAuthorship W2520709749A5013255537 @default.
• W2520709749 hasAuthorship W2520709749A5022061532 @default.
• W2520709749 hasAuthorship W2520709749A5028872300 @default.
• W2520709749 hasAuthorship W2520709749A5030107272 @default.
• W2520709749 hasAuthorship W2520709749A5034739279 @default.
• W2520709749 hasAuthorship W2520709749A5045276990 @default.
• W2520709749 hasAuthorship W2520709749A5045345910 @default.
• W2520709749 hasAuthorship W2520709749A5051301531 @default.
• W2520709749 hasAuthorship W2520709749A5067307453 @default.
• W2520709749 hasAuthorship W2520709749A5084649631 @default.
• W2520709749 hasBestOaLocation W25207097491 @default.
• W2520709749 hasConcept C121608353 @default.
• W2520709749 hasConcept C126322002 @default.
• W2520709749 hasConcept C143998085 @default.
• W2520709749 hasConcept C197934379 @default.
• W2520709749 hasConcept C2776256026 @default.
• W2520709749 hasConcept C2776694085 @default.
• W2520709749 hasConcept C2776907518 @default.
• W2520709749 hasConcept C2778087573 @default.
• W2520709749 hasConcept C2778375690 @default.
• W2520709749 hasConcept C2778570526 @default.
• W2520709749 hasConcept C2778822529 @default.
• W2520709749 hasConcept C2779438470 @default.
• W2520709749 hasConcept C2779984678 @default.
• W2520709749 hasConcept C2780580887 @default.
• W2520709749 hasConcept C71924100 @default.
• W2520709749 hasConcept C90924648 @default.
• W2520709749 hasConceptScore W2520709749C121608353 @default.
• W2520709749 hasConceptScore W2520709749C126322002 @default.
• W2520709749 hasConceptScore W2520709749C143998085 @default.
• W2520709749 hasConceptScore W2520709749C197934379 @default.
• W2520709749 hasConceptScore W2520709749C2776256026 @default.
• W2520709749 hasConceptScore W2520709749C2776694085 @default.
• W2520709749 hasConceptScore W2520709749C2776907518 @default.
• W2520709749 hasConceptScore W2520709749C2778087573 @default.
• W2520709749 hasConceptScore W2520709749C2778375690 @default.
• W2520709749 hasConceptScore W2520709749C2778570526 @default.
• W2520709749 hasConceptScore W2520709749C2778822529 @default.
• W2520709749 hasConceptScore W2520709749C2779438470 @default.
• W2520709749 hasConceptScore W2520709749C2779984678 @default.
• W2520709749 hasConceptScore W2520709749C2780580887 @default.
• W2520709749 hasConceptScore W2520709749C71924100 @default.
• W2520709749 hasConceptScore W2520709749C90924648 @default.
• W2520709749 hasIssue "8" @default.
• W2520709749 hasLocation W25207097491 @default.
• W2520709749 hasOpenAccess W2520709749 @default.
• W2520709749 hasPrimaryLocation W25207097491 @default.
• W2520709749 hasRelatedWork W1824070893 @default.
• W2520709749 hasRelatedWork W1865140249 @default.
• W2520709749 hasRelatedWork W2017389411 @default.
• W2520709749 hasRelatedWork W2025861423 @default.
• W2520709749 hasRelatedWork W2032144290 @default.
• W2520709749 hasRelatedWork W2160336497 @default.
• W2520709749 hasRelatedWork W2186047679 @default.
• W2520709749 hasRelatedWork W2239016318 @default.
• W2520709749 hasRelatedWork W2388867634 @default.
• W2520709749 hasRelatedWork W2416274847 @default.
• W2520709749 hasVolume "2" @default.
• W2520709749 isParatext "false" @default.
• W2520709749 isRetracted "false" @default.
• W2520709749 magId "2520709749" @default.
• W2520709749 workType "article" @default.